Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP7 | Q93009 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL949115 | 0.98 | HRH4 (0.41) | HRH4HRH3SLC18A3SIGMAR1MEN1 | |
| Hydrochloric Acid SCHEMBL9134652 | 0.98 | HRH4 (0.41) | HRH4HRH3SLC18A3SIGMAR1MEN1 | |
| SCHEMBL8508488 | 0.88 | HTR3A (0.39) | HRH4HRH3 | |
| SCHEMBL232190 | 0.87 | — | — | |
| SCHEMBL17604203 | 0.83 | HRH4 (0.36) | HRH4HRH3KMT2A | |
| SCHEMBL9044336 | 0.83 | — | — | |
| SCHEMBL1786021 | 0.81 | KMO (0.37) | HRH4HRH3KMT2A | |
| SCHEMBL8130205 | 0.79 | — | — | |
| SCHEMBL27034282 | 0.78 | — | — | |
| SCHEMBL7672211 | 0.78 | ESR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0494010-A1 | 1-Substituted 4-(4-imidazolyl) piperidines, process for their preparation and their therapeutic applications | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1992-07-08 | — | — | EP | claimed |
| EP-0197840-B1 | (IMIDAZOLYL-4) PIPERIDINES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1990-08-01 | — | — | EP | claimed |
| US-4707487-A | (4-imidazolyl)piperidines, the preparation thereof and their application in therapy | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1987-11-17 | — | — | US | claimed |
| JP-5247028-A | — | — | None | — | — | JP | disclosed |
| JP-5247028-A | — | — | None | — | — | JP | disclosed |
| JP-7179466-A | — | — | None | — | — | JP | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-114874186-B | Glutamine acyl cyclase isozyme inhibitor and preparation method and application thereof | 深圳大学 | 2023-07-11 | — | — | CN | disclosed |
| US-5290790-A | Histamine H3 antagonists, psychotropic action | NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1994-03-01 | — | — | US | disclosed |
| US-5280030-A | Containing 1-benz(oxazole, thiazole or imidazole)-4-imidazole piperidine compound | SYNTHELABO (FR) | 1994-01-18 | — | — | US | disclosed |
| WO-1993020061-A1 | 4-[4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1993-10-14 | — | — | WO | disclosed |
| JP-H05247028-A | NOVEL 4-(4-IMIDAZOLYL)PIPERIDINE SUBSTITUTED AT POSITION 1, PREPARATION THEREOF, AND ITS THERAPEUTIC APPLICATION | INST NATL SANTE & RECH MED <INSERM> | 1993-09-24 | — | — | JP | disclosed |
| JP-H05247028-A | NOVEL 4-(4-IMIDAZOLYL)PIPERIDINE SUBSTITUTED AT POSITION 1, PREPARATION THEREOF, AND ITS THERAPEUTIC APPLICATION | INST NATL SANTE & RECH MED <INSERM> | 1993-09-24 | — | — | JP | disclosed |
| EP-0507650-A1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1992-10-07 | — | — | EP | disclosed |
| EP-0494010-A1 | 1-Substituted 4-(4-imidazolyl) piperidines, process for their preparation and their therapeutic applications | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1992-07-08 | — | — | EP | disclosed |
| EP-0494010-A1 | 1-Substituted 4-(4-imidazolyl) piperidines, process for their preparation and their therapeutic applications | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1992-07-08 | — | — | EP | disclosed |
| US-4707487-A | (4-imidazolyl)piperidines, the preparation thereof and their application in therapy | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1987-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | HRH4 370/4885HRH3 862/4885SLC18A3 1059/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | HRH4 370/4885HRH3 862/4885SLC18A3 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.